Physician profile
Mark Waynik
NPI 1588738256
$44,825.17
in general payments reported to CMS, 2019-2025
46 companies · $7,940 in 2025
The $7,940 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,573 · 2020: $4,647 · 2021: $6,793 · 2022: $6,101 · 2023: $7,207 · 2024: $7,564 · 2025: $7,940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23K · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22,599.61 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $4,667.36 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $4,430.94 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $4,346.90 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $4,213.42 | 2020-2025 | Caplyta |
| Abbvie INC. | $3,750.20 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Neurocrine Biosciences, INC. | $3,194.71 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $2,373.86 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $2,261.84 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Corium, LLC | $1,614.12 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $1,569.97 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $1,533.04 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $1,161.68 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Indivior INC. | $1,055.55 | 2019-2025 | Sublocade, Perseris |
| Avanir Pharmaceuticals, INC. | $819.40 | 2019-2022 | |
| Eisai INC. | $797.24 | 2020-2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $733.24 | 2023-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $729.43 | 2024-2025 | Cobenfy |
| Allergan, INC. | $615.53 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $583.92 | 2019-2022 | |
| Almatica Pharma LLC | $578.92 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Supernus Pharmaceuticals, INC. | $530.95 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $417.66 | 2019-2023 | Jornay Pm |
| Bausch Health US, LLC | $323.83 | 2019-2025 | Aplenzin, Wellbutrin |
| Shire North American Group INC | $292.87 | 2019 | |
| Merck Sharp & Dohme LLC | $273.48 | 2020-2023 | Belsomra |
| Orexo US, INC. | $248.75 | 2019-2021 | |
| Braeburn INC. | $206.43 | 2024-2025 | Brixadi |
| Idorsia Pharmaceuticals US INC | $198.49 | 2022-2024 | Quviviq |
| Neos Therapeutics, Lp | $196.25 | 2019-2024 | Adzenys Xr-Odt |
| Tempus Ai, INC | $184.80 | 2024 | |
| Adlon Therapeutics L.P. | $146.84 | 2019-2021 | |
| Harmony Biosciences LLC | $137.90 | 2020-2021 | |
| Tris Pharma INC | $108.08 | 2022-2024 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $80.32 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $64.27 | 2019-2025 | Relexxii |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $62.79 | 2025 | Rejoyn |
| Arbor Pharmaceuticals, INC. | $59.88 | 2020 | |
| Amgen INC. | $54.56 | 2019-2021 | |
| Gilead Sciences, INC. | $41.90 | 2019-2020 | |
| Noven Therapeutics, LLC | $33.72 | 2020-2021 | |
| Sage Therapeutics, LLC | $33.11 | 2024 | |
| Neuronetics, INC. | $28.31 | 2019-2020 | |
| Aytu Biopharma, INC. | $20.74 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.42 | 2022 | |
| Avion Pharmaceuticals | $16.29 | 2023 | Methylphenidate Hydrochloride |
| Lilly USA, LLC | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Waynik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.